Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical…
Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical…
JAKARTA, Indonesia and NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) — LeaderMed Group (LeaderMed), a global pharmaceutical development company, and…
Patient Special Access Program continues during Health Canada reviewMELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) — CLINUVEL has filed a…
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…
Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable…
BEVERLY, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) — Thrive Bioscience, Inc., a Boston-based manufacturer of instruments for advanced imaging, analytics,…
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics DevelopmentNEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences,…
/ Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia,…
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by…